Simple sugars to complex disease-mucin-type O-glycans in cancer

Advances in Cancer Research

Volumn 126, Issue , 2015, Pages 53-135

  Kudelka, Matthew R ^a   Ju, Tongzhong ^a   Heimburg Molinaro, Jamie ^a   Cummings, Richard D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Blood group; Cancer; Carbohydrate; GalNAc; Glycan; Glycosylation; Golgi; Mucin; Tn; Tumor

Indexed keywords

CARBOHYDRATE; GLYCAN; GLYCOGEN; MONOSACCHARIDE; MUCIN; SELECTIN; SIALIC ACID DERIVATIVE; TN ANTIGEN; POLYSACCHARIDE;

ANTIGEN EXPRESSION; ARTICLE; BIOSYNTHESIS; BLOOD GROUP ABO SYSTEM; BLOOD GROUP LEWIS SYSTEM; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER THERAPY; GENETIC ASSOCIATION; GLYCOSYLATION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; MEDICAL DECISION MAKING; NEOPLASM; NONHUMAN; PATIENT CARE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; DISEASE COURSE; METABOLISM; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; GLYCOSYLATION; HUMANS; NEOPLASMS; POLYSACCHARIDES;

EID: 84923305209     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2014.11.002     Document Type: Chapter

References (321)

1. Agnese D.M., Abdessalam S.F., Burak W.E., Arnold M.W., Soble D., Hinkle G.H., et al. Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma. Annals of Surgical Oncology 2004, 11(2):197-202.
2. Akita K., Yoshida S., Ikehara Y., Shirakawa S., Toda M., Inoue M., et al. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. International Journal of Gynecological Cancer 2012, 22(4):531-538.
3. Alexander W.S., Viney E.M., Zhang J.G., Metcalf D., Kauppi M., Hyland C.D., et al. Thrombocytopenia and kidney disease in mice with a mutation in the C1galt1 gene. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(44):16442-16447.
4. Alisauskus R., Wong G.Y., Gold D.V. Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Research 1995, 55(23 Suppl.):5743s-5748s.
5. An G., Wei B., Xia B., McDaniel J.M., Ju T., Cummings R.D., et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. The Journal of Experimental Medicine 2007, 204(6):1417-1429.
6. Ando H., Matsushita T., Wakitani M., Sato T., Kodama-Nishida S., Shibata K., et al. Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo. Biological & Pharmaceutical Bulletin 2008, 31(9):1739-1744.
7. Aryal R.P., Ju T., Cummings R.D. The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of T-synthase. The Journal of Biological Chemistry 2010, 285(4):2456-2462.
8. Aryal R.P., Ju T., Cummings R.D. Tight complex formation between Cosmc chaperone and its specific client non-native T-synthase leads to enzyme activity and client-driven dissociation. The Journal of Biological Chemistry 2012, 287(19):15317-15329.
9. Aryal R.P., Ju T., Cummings R.D. Identification of a novel protein binding motif within the T-synthase for the molecular chaperone Cosmc. The Journal of Biological Chemistry 2014, 289(17):11630-11641.
10. Atkinson B.F., Ernst C.S., Herlyn M., Steplewski Z., Sears H.F., Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Research 1982, 42(11):4820-4823.
11. Aub J.C., Tieslau C., Lankester A. Reactions of normal and tumor cell surfaces to enzymes. I. wheat-germ lipase and associated mucopolysaccharides. Proceedings of the National Academy of Sciences of the United States of America 1963, 50:613-619.
12. Avci F.Y., Li X., Tsuji M., Kasper D.L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nature Medicine 2011, 17(12):1602-1609.
13. Babino A., Oppezzo P., Bianco S., Barrios E., Berois N., Navarrete H., et al. Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis. International Journal of Cancer 2000, 86(6):753-759.
14. Bennett E.P., Chen Y.W., Schwientek T., Mandel U., Schjoldager K., Cohen S.M., et al. Rescue of Drosophila melanogaster l(2)35Aa lethality is only mediated by polypeptide GalNAc-transferase pgant35A, but not by the evolutionary conserved human ortholog GalNAc-transferase-T11. Glycoconjugate Journal 2010, 27(4):435-444.
15. Bennett E.P., Mandel U., Clausen H., Gerken T.A., Fritz T.A., Tabak L.A. Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology 2012, 22(6):736-756.
16. Beresford G.W., Pavlinkova G., Booth B.J., Batra S.K., Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. International Journal of Cancer 1999, 81(6):911-917.
17. Berger A.C., Garcia M., Hoffman J.P., Regine W.F., Abrams R.A., Safran H., et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26(36):5918-5922.
18. Berois N., Mazal D., Ubillos L., Trajtenberg F., Nicolas A., Sastre-Garau X., et al. UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. The Journal of Histochemistry and Cytochemistry 2006, 54(3):317-328.
19. Berriel E., Hill M., Barcia J.J., Ubillos L., Gonzalez M., Detjen G., et al. Simple mucin-type cancer associated antigens are pre-cancerous biomarkers during 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Oncology Reports 2005, 14(1):219-227.
20. Bianco T., Farmer B.J., Sage R.E., Dobrovic A. Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood 2001, 97(11):3633-3639.
21. Bianco-Miotto T., Hussey D.J., Day T.K., O'Keefe D.S., Dobrovic A. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One 2009, 4(3):e4788.
22. Biancone L., Araki M., Araki K., Vassalli P., Stamenkovic I. Redirection of tumor metastasis by expression of E-selectin in vivo. The Journal of Experimental Medicine 1996, 183(2):581-587.
23. Bierhuizen M.F., Fukuda M. Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. Proceedings of the National Academy of Sciences of the United States of America 1992, 89(19):9326-9330.
24. Blixt O., Bueti D., Burford B., Allen D., Julien S., Hollingsworth M., et al. Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Research 2011, 13(2):R25.
25. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(6):3352-3357.
26. Bremer E.G., Schlessinger J., Hakomori S. Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. The Journal of Biological Chemistry 1986, 261(5):2434-2440.
27. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Reports 2006, 7(6):599-604.
28. Brockhausen I., Yang J.M., Burchell J., Whitehouse C., Taylor-Papadimitriou J. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. European Journal of Biochemistry 1995, 233(2):607-617.
29. Bruehl R.E., Bertozzi C.R., Rosen S.D. Minimal sulfated carbohydrates for recognition by L-selectin and the MECA-79 antibody. The Journal of Biological Chemistry 2000, 275(42):32642-32648.
30. Buck C.A., Glick M.C., Warren L. Glycopeptides from the surface of control and virus-transformed cells. Science 1971, 172(3979):169-171.
31. Butcher E.C., Rouse R.V., Coffman R.L., Nottenburg C.N., Hardy R.R., Weissman I.L. Surface phenotype of Peyer's patch germinal center cells: Implications for the role of germinal centers in B cell differentiation. Journal of Immunology 1982, 129(6):2698-2707.
32. Campbell B.J., Finnie I.A., Hounsell E.F., Rhodes J.M. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. The Journal of Clinical Investigation 1995, 95(2):571-576.
33. Cao Y., Karsten U.R., Liebrich W., Haensch W., Springer G.F., Schlag P.M. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 1995, 76(10):1700-1708.
34. Capon C., Maes E., Michalski J.C., Leffler H., Kim Y.S. Sd(a)-antigen-like structures carried on core 3 are prominent features of glycans from the mucin of normal human descending colon. The Biochemical Journal 2001, 358(Pt 3):657-664.
35. Cardillo T.M., Karacay H., Goldenberg D.M., Yeldell D., Chang C.H., Modrak D.E., et al. Improved targeting of pancreatic cancer: Experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy. Clinical Cancer Research 2004, 10(10):3552-3561.
36. Carubelli R., Bhavanandan P., Gottschalk A. Studies on glycoproteins. XIi. The O-glycosidic linkage of n-acetylgalactosamine to seryl and threonyl residues in ovine submaxillary gland glycoprotein. Biochimica et Biophysica Acta 1965, 101:67-82.
37. Chaturvedi R., Heimburg J., Yan J., Koury S., Sajjad M., Abdel-Nabi H.H., et al. Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen. Applied Radiation and Isotopes 2008, 66(3):278-287.
38. Chen K., Gentry-Maharaj A., Burnell M., Steentoft C., Marcos-Silva L., Mandel U., et al. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. Journal of Proteome Research 2013, 12(3):1408-1418.
39. Chinn P.C., Morena R.A., Santoro D.A., Kazules T., Kashmiri S.V., Schlom J., et al. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biotherapy & Radiopharmaceuticals 2006, 21(2):106-116.
40. Clausen H., Hakomori S. ABH and related histo-blood group antigens; immunochemical differences in carrier isotypes and their distribution. Vox Sanguinis 1989, 56(1):1-20.
41. Cobb B.A., Wang Q., Tzianabos A.O., Kasper D.L. Polysaccharide processing and presentation by the MHCII pathway. Cell 2004, 117(5):677-687.
42. Colcher D., Esteban J.M., Carrasquillo J.A., Sugarbaker P., Reynolds J.C., Bryant G., et al. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Research 1987, 47(4):1185-1189.
43. Colcher D., Hand P.H., Nuti M., Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proceedings of the National Academy of Sciences of the United States of America 1981, 78(5):3199-3203.
44. Colcher D., Minelli M.F., Roselli M., Muraro R., Simpson-Milenic D., Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Research 1988, 48(16):4597-4603.
45. Cummings R.D. The repertoire of glycan determinants in the human glycome. Molecular BioSystems 2009, 5(10):1087-1104.
46. Cummings R.D., Kornfeld S., Schneider W.J., Hobgood K.K., Tolleshaug H., Brown M.S., et al. Biosynthesis of N- and O-linked oligosaccharides of the low density lipoprotein receptor. The Journal of Biological Chemistry 1983, 258(24):15261-15273.
47. Cummings R.D., Pierce J.M. The challenge and promise of glycomics. Chemical Biology 2014, 21(1):1-15.
48. Dahr W., Uhlenbruck G., Bird G.W. Cryptic A-like receptor sites in human erythrocyte glycoproteins: Proposed nature of Tn-antigen. Vox Sanguinis 1974, 27(1):29-42.
49. Dall'Olio F., Chiricolo M. Sialyltransferases in cancer. Glycoconjugate Journal 2001, 18(11-12):841-850.
50. Danussi C., Coslovi A., Campa C., Mucignat M.T., Spessotto P., Uggeri F., et al. A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction. Glycobiology 2009, 19(10):1056-1067.
51. Dausset J., Moullec J., Bernard J. Acquired hemolytic anemia with polyagglutinability of red blood cells due to a new factor present in normal human serum (Anti-Tn). Blood 1959, 14:1079-1093.
52. David L., Nesland J.M., Clausen H., Carneiro F., Sobrinho-Simoes M. Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases. APMIS. Supplementum 1992, 27:162-172.
53. Dennis J.W., Laferte S. Oncodevelopmental expression of-GlcNAc beta 1-6Man alpha 1-6Man beta 1-Branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas. Cancer Research 1989, 49(4):945-950.
54. Dennis J.W., Laferte S., Waghorne C., Breitman M.L., Kerbel R.S. Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 1987, 236(4801):582-585.
55. Dennis J., Waller C., Timpl R., Schirrmacher V. Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IV and fibronectin. Nature 1982, 300(5889):274-276.
56. Desai P.R. Immunoreactive T and Tn antigens in malignancy: Role in carcinoma diagnosis, prognosis, and immunotherapy. Transfusion Medicine Reviews 2000, 14(4):312-325.
57. Do S.I., Cummings R.D. Presence of O-linked oligosaccharide on a threonine residue in the human transferrin receptor. Glycobiology 1992, 2(4):345-353.
58. Do S.I., Enns C., Cummings R.D. Human transferrin receptor contains O-linked oligosaccharides. The Journal of Biological Chemistry 1990, 265(1):114-125.
59. Ellies L.G., Tsuboi S., Petryniak B., Lowe J.B., Fukuda M., Marth J.D. Core 2 oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and inflammation. Immunity 1998, 9(6):881-890.
60. Esteban J.M., Colcher D., Sugarbaker P., Carrasquillo J.A., Bryant G., Thor A., et al. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. International Journal of Cancer 1987, 39(1):50-59.
61. Fakhro K.A., Choi M., Ware S.M., Belmont J.W., Towbin J.A., Lifton R.P., et al. Rare copy number variations in congenital heart disease patients identify unique genes in left-right patterning. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(7):2915-2920.
62. Falkenberg V.R., Alvarez K., Roman C., Fregien N. Multiple transcription initiation and alternative splicing in the 5' untranslated region of the core 2 beta1-6 N-acetylglucosaminyltransferase I gene. Glycobiology 2003, 13(6):411-418.
63. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 1985, 314(6006):53-57.
64. Fernandes B., Sagman U., Auger M., Demetrio M., Dennis J.W. Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Research 1991, 51(2):718-723.
65. Forero A., Meredith R.F., Khazaeli M.B., Carpenter D.M., Shen S., Thornton J., et al. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biotherapy & Radiopharmaceuticals 2003, 18(5):751-759.
66. Freeze H.H., Ng B.G. Golgi glycosylation and human inherited diseases. Cold Spring Harbor Perspectives in Biology 2011, 3(9):a005371.
67. Freire T., Berois N., Sonora C., Varangot M., Barrios E., Osinaga E. UDP-N-acetyl-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. International Journal of Cancer 2006, 119(6):1383-1388.
68. Fu J., Wei B., Wen T., Johansson M.E., Liu X., Bradford E., et al. Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. The Journal of Clinical Investigation 2011, 121(4):1657-1666.
69. Fukuda M. Roles of mucin-type O-glycans synthesized by core2beta1,6-N-acetylglucosaminyltransferase. Methods in Enzymology 2006, 416:332-346.
70. Fukuda M., Bothner B., Ramsamooj P., Dell A., Tiller P.R., Varki A., et al. Structures of sialylated fucosyl polylactosaminoglycans isolated from chronic myelogenous leukemia cells. The Journal of Biological Chemistry 1985, 260(24):12957-12967.
71. Fukuda M., Carlsson S.R., Klock J.C., Dell A. Structures of O-linked oligosaccharides isolated from normal granulocytes, chronic myelogenous leukemia cells, and acute myelogenous leukemia cells. The Journal of Biological Chemistry 1986, 261(27):12796-12806.
72. Fukuda M.N., Ohyama C., Lowitz K., Matsuo O., Pasqualini R., Ruoslahti E., et al. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Research 2000, 60(2):450-456.
73. Fukushima K., Hirota M., Terasaki P.I., Wakisaka A., Togashi H., Chia D., et al. Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Research 1984, 44(11):5279-5285.
74. Fuster M.M., Brown J.R., Wang L., Esko J.D. A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Research 2003, 63(11):2775-2781.
75. Fuster M.M., Esko J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nature Reviews. Cancer 2005, 5(7):526-542.
76. Ganzinger U., Deutsch E. Serum sialyltransferase levels as a parameter in the diagnosis and follow-up of gastrointestinal tumors. Cancer Research 1980, 40(4):1300-1304.
77. Gendler S.J., Lancaster C.A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. The Journal of Biological Chemistry 1990, 265(25):15286-15293.
78. Gerken T.A., Raman J., Fritz T.A., Jamison O. Identification of common and unique peptide substrate preferences for the UDP-GalNAc:Polypeptide alpha-N-acetylgalactosaminyltransferases T1 and T2 derived from oriented random peptide substrates. The Journal of Biological Chemistry 2006, 281(43):32403-32416.
79. Gilewski T.A., Ragupathi G., Dickler M., Powell S., Bhuta S., Panageas K., et al. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clinical Cancer Research 2007, 13(10):2977-2985.
80. Gill D.J., Chia J., Senewiratne J., Bard F. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. The Journal of Cell Biology 2010, 189(5):843-858.
81. Glinsky V.V., Glinsky G.V., Rittenhouse-Olson K., Huflejt M.E., Glinskii O.V., Deutscher S.L., et al. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Research 2001, 61(12):4851-4857.
82. Goel A., Baranowska-Kortylewicz J., Hinrichs S.H., Wisecarver J., Pavlinkova G., Augustine S., et al. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: Novel imaging agents for rapid in vivo localization of human colon carcinoma. Journal of Nuclear Medicine 2001, 42(10):1519-1527.
83. Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B.J., Pavlinkova G., et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Research 2000, 60(24):6964-6971.
84. Gold D.V., Alisauskas R., Sharkey R.M. Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Research 1995, 55(5):1105-1110.
85. Gold D.V., Cardillo T., Goldenberg D.M., Sharkey R.M. Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4. Critical Reviews in Oncology/Hematology 2001, 39(1-2):147-154.
86. Gold D.V., Cardillo T., Vardi Y., Blumenthal R. Radioimmunotherapy of experimental pancreatic cancer with 131I-labeled monoclonal antibody PAM4. International Journal of Cancer 1997, 71(4):660-667.
87. Gold D.V., Goldenberg D.M., Karacay H., Rossi E.A., Chang C.H., Cardillo T.M., et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Research 2008, 68(12):4819-4826.
88. Gomes J., Marcos N.T., Berois N., Osinaga E., Magalhaes A., Pinto-de-Sousa J., et al. Expression of UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. The Journal of Histochemistry and Cytochemistry 2009, 57(1):79-86.
89. Gottschalk A., Murphy W.H. Studies on mucoproteins. IV. The linkage of the prosthetic group to the protein core in ovine submaxillary gland mucoprotein. Biochimica et Biophysica Acta 1961, 46:81-90.
90. Granovsky M., Fata J., Pawling J., Muller W.J., Khokha R., Dennis J.W. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nature Medicine 2000, 6(3):306-312.
91. Graziano S.L., Tatum A.H., Gonchoroff N.J., Newman N.B., Kohman L.J. Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer. Clinical Cancer Research: An official journal of the American Association for Cancer Research 1997, 3(1):87-93.
92. Gulec S.A., Cohen S.J., Pennington K.L., Zuckier L.S., Hauke R.J., Horne H., et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: A phase I single-dose escalation trial. Clinical Cancer Research 2011, 17(12):4091-4100.
93. Guo H.B., Lee I., Kamar M., Akiyama S.K., Pierce M. Aberrant N-glycosylation of beta1 integrin causes reduced alpha5beta1 integrin clustering and stimulates cell migration. Cancer Research 2002, 62(23):6837-6845.
94. Gupta M.K., Arciaga R., Bocci L., Tubbs R., Bukowski R., Deodhar S.D. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985, 56(2):277-283. comparative study.
95. Gwin J.L., Klein-Szanto A.J., Zhang S.Y., Agarwal P., Rogatko A., Keller S.M. Loss of blood group antigen A in non-small cell lung cancer. Annals of Surgical Oncology 1994, 1(5):423-427.
96. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Research 1996, 56(23):5309-5318.
97. Hamada S., Furumoto H., Kamada M., Hirao T., Aono T. High expression rate of Tn antigen in metastatic lesions of uterine cervical cancers. Cancer Letters 1993, 74(3):167-173.
98. Han B.W., Herrin B.R., Cooper M.D., Wilson I.A. Antigen recognition by variable lymphocyte receptors. Science 2008, 321(5897):1834-1837.
99. Hanisch F.G., Uhlenbruck G., Egge H., Peter-Katalinic J. A B72.3 second-generation-monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Gal beta(1-3) [NeuAc alpha(2-6)]GalNAc. Biological Chemistry Hoppe-Seyler 1989, 370(1):21-26.
100. Hansen J.E., Lund O., Tolstrup N., Gooley A.A., Williams K.L., Brunak S. NetOglyc: Prediction of mucin type O-glycosylation sites based on sequence context and surface accessibility. Glycoconjugate Journal 1998, 15(2):115-130.
101. Harduin-Lepers A., Vallejo-Ruiz V., Krzewinski-Recchi M.A., Samyn-Petit B., Julien S., Delannoy P. The human sialyltransferase family. Biochimie 2001, 83(8):727-737.
102. Haurum J.S., Arsequell G., Lellouch A.C., Wong S.Y., Dwek R.A., McMichael A.J., et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. The Journal of Experimental Medicine 1994, 180(2):739-744.
103. Hedlund M., Padler-Karavani V., Varki N.M., Varki A. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(48):18936-18941.
104. Heimburg-Molinaro J., Priest J.W., Live D., Boons G.J., Song X., Cummings R.D., et al. Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides. International Journal for Parasitology 2013, 43(11):901-907.
105. Hemmerich S., Butcher E.C., Rosen S.D. Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody. The Journal of Experimental Medicine 1994, 180(6):2219-2226.
106. Henry S., Oriol R., Samuelsson B. Lewis histo-blood group system and associated secretory phenotypes. Vox Sanguinis 1995, 69(3):166-182.
107. Higgins E.A., Siminovitch K.A., Zhuang D.L., Brockhausen I., Dennis J.W. Aberrant O-linked oligosaccharide biosynthesis in lymphocytes and platelets from patients with the Wiskott-Aldrich syndrome. The Journal of Biological Chemistry 1991, 266(10):6280-6290.
108. Hirao T., Sakamoto Y., Kamada M., Hamada S., Aono T. Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 1993, 72(1):154-159.
109. Hirohashi S., Clausen H., Yamada T., Shimosato Y., Hakomori S. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: Its identification as Tn antigen. Proceedings of the National Academy of Sciences of the United States of America 1985, 82(20):7039-7043.
110. Hollingsworth M.A., Swanson B.J. Mucins in cancer: Protection and control of the cell surface. Nature Reviews. Cancer 2004, 4(1):45-60.
111. Hong X., Ma M.Z., Gildersleeve J.C., Chowdhury S., Barchi J.J., Mariuzza R.A., et al. Sugar-binding proteins from fish: Selection of high affinity "lambodies" that recognize biomedically relevant glycans. ACS Chemical Biology 2013, 8(1):152-160.
112. Hubert P., Heitzmann A., Viel S., Nicolas A., Sastre-Garau X., Oppezzo P., et al. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Research 2011, 71(15):5134-5143.
113. Ibrahim N.K., Yariz K.O., Bondarenko I., Manikhas A., Semiglazov V., Alyasova A., et al. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clinical Cancer Research 2011, 17(21):6822-6830.
114. Ichikawa D., Handa K., Hakomori S. Histo-blood group A/B antigen deletion/reduction vs. continuous expression in human tumor cells as correlated with their malignancy. International Journal of Cancer. Journal international du cancer 1998, 76(2):284-289.
115. Inaba N., Hiruma T., Togayachi A., Iwasaki H., Wang X.H., Furukawa Y., et al. A novel I-branching beta-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood 2003, 101(7):2870-2876.
116. Ingale S., Wolfert M.A., Gaekwad J., Buskas T., Boons G.J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nature Chemical Biology 2007, 3(10):663-667.
117. Inoue M., Ogawa H., Tanizawa O., Kobayashi Y., Tsujimoto M., Tsujimura T. Immunodetection of sialyl-Tn antigen in normal, hyperplastic and cancerous tissues of the uterine endometrium. Virchows Archiv. A, Pathological Anatomy and Histopathology 1991, 418(2):157-162.
118. Inoue M., Ton S.M., Ogawa H., Tanizawa O. Expression of Tn and sialyl-Tn antigens in tumor tissues of the ovary. American Journal of Clinical Pathology 1991, 96(6):711-716.
119. Itzkowitz S.H., Bloom E.J., Kokal W.A., Modin G., Hakomori S., Kim Y.S. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990, 66(9):1960-1966.
120. Itzkowitz S.H., Bloom E.J., Lau T.S., Kim Y.S. Mucin associated Tn and sialosyl-Tn antigen expression in colorectal polyps. Gut 1992, 33(4):518-523.
121. Itzkowitz S.H., Marshall A., Kornbluth A., Harpaz N., McHugh J.B., Ahnen D., et al. Sialosyl-Tn antigen: Initial report of a new marker of malignant progression in long-standing ulcerative colitis. Gastroenterology 1995, 109(2):490-497.
122. Itzkowitz S.H., Young E., Dubois D., Harpaz N., Bodian C., Chen A., et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: A retrospective case-control study. Gastroenterology 1996, 110(3):694-704.
123. Itzkowitz S.H., Yuan M., Fukushi Y., Palekar A., Phelps P.C., Shamsuddin A.M., et al. Lewisx- and sialylated Lewisx-related antigen expression in human malignant and nonmalignant colonic tissues. Cancer Research 1986, 46(5):2627-2632.
124. Itzkowitz S.H., Yuan M., Montgomery C.K., Kjeldsen T., Takahashi H.K., Bigbee W.L., et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Research 1989, 49(1):197-204.
125. Iwai T., Inaba N., Naundorf A., Zhang Y., Gotoh M., Iwasaki H., et al. Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. The Journal of Biological Chemistry 2002, 277(15):12802-12809.
126. Iwaya Y., Hasebe O., Koide N., Kitahara K., Suga T., Shinji A., et al. Reduced expression of alphaGlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma-A possible biomarker to predict the malignant potential of Barrett's oesophagus. Histopathology 2014, 64(4):536-546.
127. Izumi Y., Taniuchi Y., Tsuji T., Smith C.W., Nakamori S., Fidler I.J., et al. Characterization of human colon carcinoma variant cells selected for sialyl Lex carbohydrate antigen: Liver colonization and adhesion to vascular endothelial cells. Experimental Cell Research 1995, 216(1):215-221.
128. Jass J.R., Allison L.M., Edgar S. Monoclonal antibody TKH2 to the cancer-associated epitope sialosyl Tn shows cross-reactivity with variants of normal colorectal goblet cell mucin. Pathology 1994, 26(4):418-422.
129. Johnson V.G., Schlom J., Paterson A.J., Bennett J., Magnani J.L., Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Research 1986, 46(2):850-857.
130. Ju T., Aryal R.P., Kudelka M.R., Wang Y., Cummings R.D. The Cosmc connection to the Tn antigen in cancer. Cancer Biomarkers 2014, 14(1):63-81.
131. Ju T., Aryal R.P., Stowell C.J., Cummings R.D. Regulation of protein O-glycosylation by the endoplasmic reticulum-localized molecular chaperone Cosmc. The Journal of Cell Biology 2008, 182(3):531-542.
132. Ju T., Brewer K., D'Souza A., Cummings R.D., Canfield W.M. Cloning and expression of human core 1 beta1,3-galactosyltransferase. The Journal of Biological Chemistry 2002, 277(1):178-186.
133. Ju T., Cummings R.D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(26):16613-16618.
134. Ju T., Cummings R.D. Protein glycosylation: Chaperone mutation in Tn syndrome. Nature 2005, 437(7063):1252.
135. Ju T., Lanneau G.S., Gautam T., Wang Y., Xia B., Stowell S.R., et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Research 2008, 68(6):1636-1646.
136. Ju T., Otto V.I., Cummings R.D. The Tn antigen-structural simplicity and biological complexity. Angewandte Chemie (International Ed. in English) 2011, 50(8):1770-1791.
137. Ju T., Wang Y., Aryal R.P., Lehoux S.D., Ding X., Kudelka M.R., et al. Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics. Clinical Applications 2013, 7(9-10):618-631.
138. Ju T., Zheng Q., Cummings R.D. Identification of core 1 O-glycan T-synthase from Caenorhabditis elegans. Glycobiology 2006, 16(10):947-958.
139. Julenius K., Molgaard A., Gupta R., Brunak S. Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 2005, 15(2):153-164.
140. Julien S., Krzewinski-Recchi M.A., Harduin-Lepers A., Gouyer V., Huet G., Le Bourhis X., et al. Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc alpha2,6-sialyltransferase (ST6GalNac I) cDNA. Glycoconjugate Journal 2001, 18(11-12):883-893.
141. Julien S., Videira P.A., Delannoy P. Sialyl-tn in cancer: (How) Did we miss the target?. Biomolecules 2012, 2(4):435-466.
142. Kakeji Y., Tsujitani S., Mori M., Maehara Y., Sugimachi K. Helix pomatia agglutinin binding activity is a predictor of survival time for patients with gastric carcinoma. Cancer 1991, 68(11):2438-2442.
143. Kannagi R. Molecular mechanism for cancer-associated induction of sialyl Lewis X and sialyl Lewis A expression-The Warburg effect revisited. Glycoconjugate Journal 2004, 20(5):353-364. review.
144. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England Journal of Medicine 2010, 363(5):411-422.
145. Karacay H., Sharkey R.M., Gold D.V., Ragland D.R., McBride W.J., Rossi E.A., et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. Journal of Nuclear Medicine 2009, 50(12):2008-2016.
146. Karasawa F., Shiota A., Goso Y., Kobayashi M., Sato Y., Masumoto J., et al. Essential role of gastric gland mucin in preventing gastric cancer in mice. The Journal of Clinical Investigation 2012, 122(3):923-934.
147. Kawakubo M., Ito Y., Okimura Y., Kobayashi M., Sakura K., Kasama S., et al. Natural antibiotic function of a human gastric mucin against Helicobacter pylori infection. Science 2004, 305(5686):1003-1006.
148. Kellokumpu S., Sormunen R., Kellokumpu I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: Dependence on intra-Golgi pH. FEBS Letters 2002, 516(1-3):217-224.
149. Kim G.E., Bae H.I., Park H.U., Kuan S.F., Crawley S.C., Ho J.J., et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002, 123(4):1052-1060.
150. Kim Y.J., Borsig L., Varki N.M., Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(16):9325-9330.
151. Kingsley D.M., Kozarsky K.F., Hobbie L., Krieger M. Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNAc 4-epimerase deficient mutant. Cell 1986, 44(5):749-759.
152. Kingsley D.M., Krieger M. Receptor-mediated endocytosis of low density lipoprotein: Somatic cell mutants define multiple genes required for expression of surface-receptor activity. Proceedings of the National Academy of Sciences of the United States of America 1984, 81(17):5454-5458.
153. Kjeldsen T., Clausen H., Hirohashi S., Ogawa T., Iijima H., Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Research 1988, 48(8):2214-2220.
154. Klein P.J., Newman R.A., Muller P., Uhlenbruck G., Citoler P., Schaefer H.E., et al. The presence and significance of the Thomsen-Friedenreich antigen in mammary gland. II. Its topochemistry in normal, hyperplastic and carcinoma tissue of the breast. Journal of Cancer Research and Clinical Oncology 1979, 93(2):205-214. comparative study.
155. Kobayashi H., Terao T., Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. Journal of Clinical Oncology 1992, 10(1):95-101.
156. Konno A., Hoshino Y., Terashima S., Motoki R., Kawaguchi T. Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis. Clinical & Experimental Metastasis 2002, 19(1):61-70.
157. Kozarsky K., Kingsley D., Krieger M. Use of a mutant cell line to study the kinetics and function of O-linked glycosylation of low density lipoprotein receptors. Proceedings of the National Academy of Sciences of the United States of America 1988, 85(12):4335-4339.
158. Kubota T., Matsushita T., Niwa R., Kumagai I., Nakamura K. Novel anti-Tn single-chain Fv-Fc fusion proteins derived from immunized phage library and antibody Fc domain. Anticancer Research 2010, 30(9):3397-3405.
159. Kufe D.W. Mucins in cancer: Function, prognosis and therapy. Nature Reviews. Cancer 2009, 9(12):874-885.
160. Kufe D., Inghirami G., Abe M., Hayes D., Justi-Wheeler H., Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984, 3(3):223-232.
161. Kukowska-Latallo J.F., Larsen R.D., Nair R.P., Lowe J.B. A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase. Genes & Development 1990, 4(8):1288-1303.
162. Kumamoto K., Goto Y., Sekikawa K., Takenoshita S., Ishida N., Kawakita M., et al. Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Research 2001, 61(11):4620-4627.
163. Kumar R., Camphausen R.T., Sullivan F.X., Cumming D.A. Core2 beta-1,6-N-acetylglucosaminyltransferase enzyme activity is critical for P-selectin glycoprotein ligand-1 binding to P-selectin. Blood 1996, 88(10):3872-3879.
164. Laack E., Nikbakht H., Peters A., Kugler C., Jasiewicz Y., Edler L., et al. Lectin histochemistry of resected adenocarcinoma of the lung: Helix pomatia agglutinin binding is an independent prognostic factor. The American Journal of Pathology 2002, 160(3):1001-1008.
165. Langkilde N.C., Wolf H., Clausen H., Kjeldsen T., Orntoft T.F. Nuclear volume and expression of T-antigen, sialosyl-Tn-antigen, and Tn-antigen in carcinoma of the human bladder. Relation to tumor recurrence and progression. Cancer 1992, 69(1):219-227.
166. Larsson J.M., Karlsson H., Sjovall H., Hansson G.C. A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. Glycobiology 2009, 19(7):756-766.
167. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Journal of Clinical Oncology 2005, 23(10):2123-2129.
168. Lee J.S., Ro J.Y., Sahin A.A., Hong W.K., Brown B.W., Mountain C.F., et al. Expression of blood-group antigen A-a favorable prognostic factor in non-small-cell lung cancer. The New England Journal of Medicine 1991, 324(16):1084-1090.
169. Lefebvre J.C., Giordanengo V., Limouse M., Doglio A., Cucchiarini M., Monpoux F., et al. Altered glycosylation of leukosialin, CD43, in HIV-1-infected cells of the CEM line. The Journal of Experimental Medicine 1994, 180(5):1609-1617.
170. Leppanen A., Mehta P., Ouyang Y.B., Ju T., Helin J., Moore K.L., et al. A novel glycosulfopeptide binds to P-selectin and inhibits leukocyte adhesion to P-selectin. The Journal of Biological Chemistry 1999, 274(35):24838-24848.
171. Ma X.C., Terata N., Kodama M., Jancic S., Hosokawa Y., Hattori T. Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. European Journal of Cancer 1993, 29A(13):1820-1823.
172. Magnani J.L., Nilsson B., Brockhaus M., Zopf D., Steplewski Z., Koprowski H., et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. The Journal of Biological Chemistry 1982, 257(23):14365-14369.
173. Magnani J.L., Steplewski Z., Koprowski H., Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Research 1983, 43(11):5489-5492.
174. Marcos N.T., Bennett E.P., Gomes J., Magalhaes A., Gomes C., David L., et al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Frontiers in Bioscience 2011, 3:1443-1455.
175. Marcos N.T., Pinho S., Grandela C., Cruz A., Samyn-Petit B., Harduin-Lepers A., et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Research 2004, 64(19):7050-7057.
176. Marcus D.M., Cass L.E. Glycosphingolipids with Lewis blood group activity: Uptake by human erythrocytes. Science 1969, 164(3879):553-555.
177. Mariani G., Molea N., Bacciardi D., Boggi U., Fornaciari G., Campani D., et al. Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer. Cancer Research 1995, 55(23 Suppl.):5911s-5915s.
178. Marsh W.L. Anti-i: A cold antibody defining the Ii relationship in human red cells. British Journal of Haematology 1961, 7:200-209.
179. Matsumoto S., Imaeda Y., Umemoto S., Kobayashi K., Suzuki H., Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. British Journal of Cancer 2002, 86(2):161-167.
180. Matsushita Y., Cleary K.R., Ota D.M., Hoff S.D., Irimura T. Sialyl-dimeric Lewis-X antigen expressed on mucin-like glycoproteins in colorectal cancer metastases. Laboratory Investigation; A Journal of Technical Methods and Pathology 1990, 63(6):780-791.
181. Meezan E., Wu H.C., Black P.H., Robbins P.W. Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry 1969, 8(6):2518-2524.
182. Mi R., Song L., Wang Y., Ding X., Zeng J., Lehoux S., et al. Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing tn antigen. The Journal of Biological Chemistry 2012, 287(49):41523-41533.
183. Milenic D.E., Yokota T., Filpula D.R., Finkelman M.A., Dodd S.W., Wood J.F., et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Research 1991, 51(23 Pt. 1):6363-6371.
184. Miyake M., Taki T., Hitomi S., Hakomori S. Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. The New England Journal of Medicine 1992, 327(1):14-18.
185. Morita N., Yajima Y., Asanuma H., Nakada H., Fujita-Yamaguchi Y. Inhibition of cancer cell growth by anti-Tn monoclonal antibody MLS128. Bioscience Trends 2009, 3(1):32-37.
186. Motoo Y., Kawakami H., Watanabe H., Satomura Y., Ohta H., Okai T., et al. Serum sialyl-Tn antigen levels in patients with digestive cancers. Oncology 1991, 48(4):321-326.
187. Muthana S.M., Campbell C.T., Gildersleeve J.C. Modifications of glycans: Biological significance and therapeutic opportunities. ACS Chemical Biology 2012, 7(1):31-43.
188. Nagy P., Vereb G., Sebestyen Z., Horvath G., Lockett S.J., Damjanovich S., et al. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. Journal of Cell Science 2002, 115(Pt. 22):4251-4262.
189. Nakagoe T., Fukushima K., Nanashima A., Sawai T., Tsuji T., Jibiki M.A., et al. Comparison of the expression of ABH/Lewis-related antigens in polypoid and non-polypoid growth types of colorectal carcinoma. Journal of Gastroenterology and Hepatology 2001, 16(2):176-183.
190. Nakagoe T., Nanashima A., Sawai T., Tuji T., Ohbatake M., Jibiki M., et al. Expression of blood group antigens A, B and H in carcinoma tissue correlates with a poor prognosis for colorectal cancer patients. Journal of Cancer Research and Clinical Oncology 2000, 126(7):375-382.
191. Nakamori S., Kameyama M., Imaoka S., Furukawa H., Ishikawa O., Sasaki Y., et al. Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: Clinicopathological and immunohistochemical study. Cancer Research 1993, 53(15):3632-3637.
192. Nakamori S., Kameyama M., Imaoka S., Furukawa H., Ishikawa O., Sasaki Y., et al. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Diseases of the Colon and Rectum 1997, 40(4):420-431.
193. Nakamoto Y., Saga T., Sakahara H., Yao Z., Zhang M., Sato N., et al. Three-step tumor imaging with biotinylated monoclonal antibody, streptavidin and 111In-DTPA-biotin. Nuclear Medicine and Biology 1998, 25(2):95-99.
194. Nakayama J. Dual roles of gastric gland mucin-specific O-glycans in prevention of gastric cancer. Acta Histochemica et Cytochemica 2014, 47(1):1-9.
195. Nakayama T., Watanabe M., Katsumata T., Teramoto T., Kitajima M. Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 1995, 75(8):2051-2056.
196. Nanashima A., Yamaguchi H., Nakagoe T., Matsuo S., Sumida Y., Tsuji T., et al. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas. Journal of Hepato-Biliary-Pancreatic Surgery 1999, 6(4):391-395.
197. Napoletano C., Rughetti A., Agervig Tarp M.P., Coleman J., Bennett E.P., Picco G., et al. Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Research 2007, 67(17):8358-8367.
198. Narimatsu Y., Kubota T., Furukawa S., Shimojima M., Iwasaki H., Tozawa Y., et al. Co-translational function of Cosmc, core 1 synthase specific molecular chaperone, revealed by a cell-free translation system. FEBS Letters 2011, 585(9):1276-1280.
199. Nuti M., Teramoto Y.A., Mariani-Costantini R., Hand P.H., Colcher D., Schlom J. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. International Journal of Cancer. Journal international du cancer 1982, 29(5):539-545.
200. O'Boyle K.P., Markowitz A.L., Khorshidi M., Lalezari P., Longenecker B.M., Lloyd K.O., et al. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2->6) T antigens. Hybridoma 1996, 15(6):401-408.
201. Ogata S., Maimonis P.J., Itzkowitz S.H. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Research 1992, 52(17):4741-4746.
202. Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126(5):855-867.
203. Oh-Uti K. Polysaccharides and a glycidamin in the tissue of gastric cancer. The Tohoku Journal of Experimental Medicine 1949, 51(3-4):297-304.
204. Orntoft T.F., Wolf H., Watkins W.M. Activity of the human blood group ABO, Se, H, Le, and X gene-encoded glycosyltransferases in normal and malignant bladder urothelium. Cancer Research 1988, 48(15):4427-4433.
205. Orr S.L., Le D., Long J.M., Sobieszczuk P., Ma B., Tian H., et al. A phenotype survey of 36 mutant mouse strains with gene-targeted defects in glycosyltransferases or glycan-binding proteins. Glycobiology 2013, 23(3):363-380.
206. Osako M., Yonezawa S., Siddiki B., Huang J., Ho J.J., Kim Y.S., et al. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993, 71(7):2191-2199.
207. Ozanne B., Sambrook J. Binding of radioactively labelled concanavalin A and wheat germ agglutinin to normal and virus-transformed cells. Nature: New Biology 1971, 232(31):156-160.
208. Pai L.H., Wittes R., Setser A., Willingham M.C., Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nature Medicine 1996, 2(3):350-353.
209. Pang P.C., Chiu P.C., Lee C.L., Chang L.Y., Panico M., Morris H.R., et al. Human sperm binding is mediated by the sialyl-Lewis(x) oligosaccharide on the zona pellucida. Science 2011, 333(6050):1761-1764.
210. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., et al. Helicobacter pylori infection and the risk of gastric carcinoma. The New England Journal of Medicine 1991, 325(16):1127-1131.
211. Partridge E.A., Le Roy C., Di Guglielmo G.M., Pawling J., Cheung P., Granovsky M., et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 2004, 306(5693):120-124.
212. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nature Reviews. Cancer 2006, 6(7):559-565.
213. Pastan I., Lovelace E.T., Gallo M.G., Rutherford A.V., Magnani J.L., Willingham M.C. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Research 1991, 51(14):3781-3787.
214. Patani N., Jiang W., Mokbel K. Prognostic utility of glycosyltransferase expression in breast cancer. Cancer Genomics Proteomics 2008, 5(6):333-340.
215. Pavlinkova G., Beresford G.W., Booth B.J., Batra S.K., Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. Journal of Nuclear Medicine 1999, 40(9):1536-1546.
216. Pavlinkova G., Booth B.J., Batra S.K., Colcher D. Radioimmunotherapy of human colon cancer xenografts using a dimeric single-chain Fv antibody construct. Clinical Cancer Research 1999, 5(9):2613-2619.
217. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. International Journal of Cancer 2011, 128(8):1860-1871.
218. Pegram M.D., Borges V.F., Ibrahim N., Fuloria J., Shapiro C., Perez S., et al. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Research 2009, 11(5):R73.
219. Petrosyan A., Ali M.F., Cheng P.W. Glycosyltransferase-specific Golgi-targeting mechanisms. The Journal of Biological Chemistry 2012, 287(45):37621-37627.
220. Phelan C.M., Tsai Y.Y., Goode E.L., Vierkant R.A., Fridley B.L., Beesley J., et al. Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: The Ovarian Cancer Association Consortium. Cancer Epidemiology, Biomarkers & Prevention 2010, 19(2):600-604.
221. Podolsky D.K. Oligosaccharide structures of isolated human colonic mucin species. The Journal of Biological Chemistry 1985, 260(29):15510-15515.
222. Priatel J.J., Chui D., Hiraoka N., Simmons C.J., Richardson K.B., Page D.M., et al. The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity 2000, 12(3):273-283.
223. Prokop O., Uhlenbruck G. N-acetyl-D-galactosamine in tumor cell membranes: Demonstration by means of Helix agglutinins. Die Medizinische Welt 1969, 46:2515-2519.
224. Radhakrishnan P., Dabelsteen S., Madsen F.B., Francavilla C., Kopp K.L., Steentoft C., et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(39):E4066-E4075.
225. Reepmaker J. The relation between polyagglutinability of erythrocytes in vivo and the Hubener-Thomsen-Friedenreich phenomenon. Journal of Clinical Pathology 1952, 5(3):266-270.
226. Reis C.A., Osorio H., Silva L., Gomes C., David L. Alterations in glycosylation as biomarkers for cancer detection. Journal of Clinical Pathology 2010, 63(4):322-329.
227. Roth J., Wang Y., Eckhardt A.E., Hill R.L. Subcellular localization of the UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-mediated O-glycosylation reaction in the submaxillary gland. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(19):8935-8939.
228. Rottger S., White J., Wandall H.H., Olivo J.C., Stark A., Bennett E.P., et al. Localization of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O-linked glycosylation throughout the Golgi apparatus. Journal of Cell Science 1998, 111(Pt. 1):45-60.
229. Roxby D.J., Pfeiffer M.B., Morley A.A., Kirkland M.A. Expression of the Tn antigen in myelodysplasia, lymphoma, and leukemia. Transfusion 1992, 32(9):834-838. case reports.
230. Sabbatini P.J., Ragupathi G., Hood C., Aghajanian C.A., Juretzka M., Iasonos A., et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research 2007, 13(14):4170-4177.
231. Sahin U., Tureci O., Schmitt H., Cochlovius B., Johannes T., Schmits R., et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(25):11810-11813.
232. Salouti M., Rajabi H., Babaei M.H., Rasaee M.J. Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. Nuclear Medicine and Biology 2008, 35(7):763-768.
233. Santer U.V., Gilbert F., Glick M.C. Change in glycosylation of membrane glycoproteins after transfection of NIH 3T3 with human tumor DNA. Cancer Research 1984, 44(9):3730-3735.
234. Sasaki H., Bothner B., Dell A., Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. The Journal of Biological Chemistry 1987, 262(25):12059-12076.
235. Schauer H., Gottschalk A. Studies on glycoproteins. XVII. Purification of O-seryl-N-acetylgalactosaminide glycohydrolase. Its complete separation from N-acetyl-beta-D-hexosaminidase and proteases. Biochimica et Biophysica Acta 1968, 156(2):304-310.
236. Schjoldager K.T., Clausen H. Site-specific protein O-glycosylation modulates proprotein processing-deciphering specific functions of the large polypeptide GalNAc-transferase gene family. Biochimica et Biophysica Acta 2012, 1820(12):2079-2094.
237. Schjoldager K.T., Vakhrushev S.Y., Kong Y., Steentoft C., Nudelman A.S., Pedersen N.B., et al. Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCells. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(25):9893-9898.
238. Schroeder J.A., Masri A.A., Adriance M.C., Tessier J.C., Kotlarczyk K.L., Thompson M.C., et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004, 23(34):5739-5747.
239. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., et al. gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. The New England Journal of Medicine 2011, 364(22):2119-2127.
240. Schwientek T., Nomoto M., Levery S.B., Merkx G., van Kessel A.G., Bennett E.P., et al. Control of O-glycan branch formation. Molecular cloning of human cDNA encoding a novel beta1,6-N-acetylglucosaminyltransferase forming core 2 and core 4. The Journal of Biological Chemistry 1999, 274(8):4504-4512.
241. Schwientek T., Yeh J.C., Levery S.B., Keck B., Merkx G., van Kessel A.G., et al. Control of O-glycan branch formation. Molecular cloning and characterization of a novel thymus-associated core 2 beta1, 6-n-acetylglucosaminyltransferase. The Journal of Biological Chemistry 2000, 275(15):11106-11113.
242. Sekine M., Nara K., Suzuki A. Tissue-specific regulation of mouse core 2 beta-1,6-N-acetylglucosaminyltransferase. The Journal of Biological Chemistry 1997, 272(43):27246-27252.
243. Sellers T.A., Huang Y., Cunningham J., Goode E.L., Sutphen R., Vierkant R.A., et al. Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention 2008, 17(2):397-404.
244. Shimodaira K., Nakayama J., Nakamura N., Hasebe O., Katsuyama T., Fukuda M. Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: Role of O-glycans in tumor progression. Cancer Research 1997, 57(23):5201-5206.
245. Shiratsu K., Higuchi K., Nakayama J. Loss of gastric gland mucin-specific O-glycan is associated with progression of differentiated-type adenocarcinoma of the stomach. Cancer Science 2014, 105(1):126-133.
246. Siddiqui J., Abe M., Hayes D., Shani E., Yunis E., Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proceedings of the National Academy of Sciences of the United States of America 1988, 85(7):2320-2323.
247. Slavin-Chiorini D.C., Horan Hand P.H., Kashmiri S.V., Calvo B., Zaremba S., Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. International Journal of Cancer 1993, 53(1):97-103.
248. Slavin-Chiorini D.C., Kashmiri S.V., Lee H.S., Milenic D.E., Poole D.J., Bernon E., et al. A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biotherapy & Radiopharmaceuticals 1997, 12(5):305-316.
249. Slavin-Chiorini D.C., Kashmiri S.V., Schlom J., Calvo B., Shu L.M., Schott M.E., et al. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Research 1995, 55(23 Suppl.):5957s-5967s.
250. Somers W.S., Tang J., Shaw G.D., Camphausen R.T. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell 2000, 103(3):467-479.
251. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., et al. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16(2):96-107.
252. Spicer A.P., Rowse G.J., Lidner T.K., Gendler S.J. Delayed mammary tumor progression in Muc-1 null mice. The Journal of Biological Chemistry 1995, 270(50):30093-30101.
253. Springer G.F. T and Tn, general carcinoma autoantigens. Science 1984, 224(4654):1198-1206.
254. Springer G.F., Desai P.R., Banatwala I. Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. Journal of the National Cancer Institute 1975, 54(2):335-339.
255. Springer G.F., Desai P.R., Tegtmeyer H., Spencer B.D., Scanlon E.F. Pancarcinoma T/Tn antigen detects human carcinoma long before biopsy does and its vaccine prevents breast carcinoma recurrence. Annals of the New York Academy of Sciences 1993, 690:355-357.
256. Springer G.F., Murthy M.S., Desai P.R., Scanlon E.F. Breast cancer patient's cell-mediated immune response to Thomsen-Friedenreich (T) antigen. Cancer 1980, 45(12):2949-2954.
257. St Hill C.A., Baharo-Hassan D., Farooqui M. C2-O-sLeX glycoproteins are E-selectin ligands that regulate invasion of human colon and hepatic carcinoma cells. PLoS One 2011, 6(1):e16281.
258. St Hill C.A., Farooqui M., Mitcheltree G., Gulbahce H.E., Jessurun J., Cao Q., et al. The high affinity selectin glycan ligand C2-O-sLex and mRNA transcripts of the core 2 beta-1,6-N-acetylglucosaminyltransferase (C2GnT1) gene are highly expressed in human colorectal adenocarcinomas. BMC Cancer 2009, 9:79.
259. Stanley P., Cummings R.D. Structures common to different glycans. Essentials of glycobiology 2009, Cold Spring Harbor, New York. 2nd ed. A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart, M.E. Etzler (Eds.).
260. Steentoft C., Vakhrushev S.Y., Joshi H.J., Kong Y., Vester-Christensen M.B., Schjoldager K.T., et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. The EMBO Journal 2013, 32(10):1478-1488.
261. Stone E.L., Ismail M.N., Lee S.H., Luu Y., Ramirez K., Haslam S.M., et al. Glycosyltransferase function in core 2-type protein O glycosylation. Molecular and Cellular Biology 2009, 29(13):3770-3782.
262. Stowell S.R., Arthur C.M., Dias-Baruffi M., Rodrigues L.C., Gourdine J.P., Heimburg-Molinaro J., et al. Innate immune lectins kill bacteria expressing blood group antigen. Nature Medicine 2010, 16(3):295-301.
263. Stowell S.R., Arthur C.M., McBride R., Berger O., Razi N., Heimburg-Molinaro J., et al. Microbial glycan microarrays define key features of host-microbial interactions. Nature Chemical Biology 2014, 10(6):470-476.
264. Swallow D.M., Gendler S., Griffiths B., Corney G., Taylor-Papadimitriou J., Bramwell M.E. The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM. Nature 1987, 328(6125):82-84.
265. Tabak L.A. The role of mucin-type O-glycans in eukaryotic development. Seminars in Cell & Developmental Biology 2010, 21(6):616-621.
266. Tai T., Paulson J.C., Cahan L.D., Irie R.F. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proceedings of the National Academy of Sciences of the United States of America 1983, 80(17):5392-5396.
267. Takada A., Ohmori K., Takahashi N., Tsuyuoka K., Yago A., Zenita K., et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl Lewis A. Biochemical and Biophysical Research Communications 1991, 179(2):713-719.
268. Takada A., Ohmori K., Yoneda T., Tsuyuoka K., Hasegawa A., Kiso M., et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Research 1993, 53(2):354-361.
269. Takahashi H.K., Metoki R., Hakomori S. Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen. Cancer Research 1988, 48(15):4361-4367.
270. Tanaka K., Bertolini M., Pigman W. Serine and threonine glycosidic linkages in bovine submaxillary mucin. Biochemical and Biophysical Research Communications 1964, 16(5):404-409.
271. Tangvoranuntakul P., Gagneux P., Diaz S., Bardor M., Varki N., Varki A., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(21):12045-12050.
272. Ten Hagen K.G., Tran D.T. A UDP-GalNAc:Polypeptide N-acetylgalactosaminyltransferase is essential for viability in Drosophila melanogaster. The Journal of Biological Chemistry 2002, 277(25):22616-22622.
273. Tenno M., Ohtsubo K., Hagen F.K., Ditto D., Zarbock A., Schaerli P., et al. Initiation of protein O glycosylation by the polypeptide GalNAcT-1 in vascular biology and humoral immunity. Molecular and Cellular Biology 2007, 27(24):8783-8796.
274. Teslovich T.M., Musunuru K., Smith A.V., Edmondson A.C., Stylianou I.M., Koseki M., et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010, 466(7307):707-713.
275. The EUROGAST Study Group An international association between Helicobacter pylori infection and gastric cancer. Lancet 1993, 341(8857):1359-1362.
276. Therkildsen M.H., Mandel U., Christensen M., Dabelsteen E. Simple mucin-type Tn and sialosyl-Tn carbohydrate antigens in salivary gland carcinomas. Cancer 1993, 72(4):1147-1154.
277. Thomsson K.A., Holmen-Larsson J.M., Angstrom J., Johansson M.E., Xia L., Hansson G.C. Detailed O-glycomics of the Muc2 mucin from colon of wild-type, core 1- and core 3-transferase-deficient mice highlights differences compared with human MUC2. Glycobiology 2012, 22(8):1128-1139.
278. Thor A., Ohuchi N., Szpak C.A., Johnston W.W., Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Research 1986, 46(6):3118-3124.
279. Thun M.J., DeLancey J.O., Center M.M., Jemal A., Ward E.M. The global burden of cancer: priorities for prevention. Carcinogenesis 2010, 31(1):100-110.
280. Tian E., Ten Hagen K.G. Recent insights into the biological roles of mucin-type O-glycosylation. Glycoconjugate Journal 2009, 26(3):325-334.
281. Topaz O., Shurman D.L., Bergman R., Indelman M., Ratajczak P., Mizrachi M., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nature Genetics 2004, 36(6):579-581.
282. Tran D.T., Zhang L., Zhang Y., Tian E., Earl L.A., Ten Hagen K.G. Multiple members of the UDP-GalNAc: Polypeptide N-acetylgalactosaminyltransferase family are essential for viability in Drosophila. The Journal of Biological Chemistry 2012, 287(8):5243-5252.
283. van Beek W.P., Smets L.A., Emmelot P. Increased sialic acid density in surface glycoprotein of transformed and malignant cells-a general phenomenon?. Cancer Research 1973, 33(11):2913-2922.
284. van der Post S., Subramani D.B., Backstrom M., Johansson M.E., Vester-Christensen M.B., Mandel U., et al. Site-specific O-glycosylation on the MUC2 mucin protein inhibits cleavage by the Porphyromonas gingivalis secreted cysteine protease (RgpB). The Journal of Biological Chemistry 2013, 288(20):14636-14646.
285. van Vliet S.J., Paessens L.C., Broks-van den Berg V.C., Geijtenbeek T.B., van Kooyk Y. The C-type lectin macrophage galactose-type lectin impedes migration of immature APCs. Journal of Immunology 2008, 181(5):3148-3155.
286. Varki A., Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 2006, 16(1):1R-27R.
287. Vavasseur F., Yang J.M., Dole K., Paulsen H., Brockhausen I. Synthesis of O-glycan core 3: Characterization of UDP-GlcNAc: GalNAc-R beta 3-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines. Glycobiology 1995, 5(3):351-357.
288. Vazquez-Martin C., Cuevas E., Gil-Martin E., Fernandez-Briera A. Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology 2004, 67(2):159-165.
289. Velcich A., Yang W., Heyer J., Fragale A., Nicholas C., Viani S., et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295(5560):1726-1729.
290. von Mensdorff-Pouilly S., Petrakou E., Kenemans P., van Uffelen K., Verstraeten A.A., Snijdewint F.G., et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. International Journal of Cancer 2000, 86(5):702-712.
291. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine 2007, 13(9):1070-1077.
292. Wandall H.H., Blixt O., Tarp M.A., Pedersen J.W., Bennett E.P., Mandel U., et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Research 2010, 70(4):1306-1313.
293. Wandall H.H., Hassan H., Mirgorodskaya E., Kristensen A.K., Roepstorff P., Bennett E.P., et al. Substrate specificities of three members of the human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase family, GalNAc-T1, -T2, and -T3. The Journal of Biological Chemistry 1997, 272(38):23503-23514.
294. Wang Y., Jobe S.M., Ding X., Choo H., Archer D.R., Mi R., et al. Platelet biogenesis and functions require correct protein O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(40):16143-16148.
295. Wang Y., Ju T., Ding X., Xia B., Wang W., Xia L., et al. Cosmc is an essential chaperone for correct protein O-glycosylation. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(20):9228-9233.
296. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. The New England Journal of Medicine 2005, 353(12):1224-1235.
297. Wargovich M.J., Chang P., Velasco M., Sinicrope F., Eisenbrodt E., Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Applied Immunohistochemistry & Molecular Morphology 2004, 12(4):350-355.
298. Warren L., Buck C.A., Tuszynski G.P. Glycopeptide changes and malignant transformation. A possible role for carbohydrate in malignant behavior. Biochimica et Biophysica Acta 1978, 516(1):97-127.
299. Watanabe K., Hakomori S.I., Childs R.A., Feizi T. Characterization of a blood group I-active ganglioside. Structural requirements for I and i specificities. The Journal of Biological Chemistry 1979, 254(9):3221-3228.
300. Welinder C., Baldetorp B., Borrebaeck C., Fredlund B.M., Jansson B. A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity. Glycobiology 2011, 21(8):1097-1107.
301. Werther J.L., Rivera-MacMurray S., Bruckner H., Tatematsu M., Itzkowitz S.H. Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. British Journal of Cancer 1994, 69(3):613-616.
302. Werther J.L., Tatematsu M., Klein R., Kurihara M., Kumagai K., Llorens P., et al. Sialosyl-Tn antigen as a marker of gastric cancer progression: An international study. International Journal of Cancer. Journal international du cancer 1996, 69(3):193-199.
303. Wu C., Guo X., Wang W., Wang Y., Shan Y., Zhang B., et al. N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer 2010, 10:123.
304. Xia L., Ju T., Westmuckett A., An G., Ivanciu L., McDaniel J.M., et al. Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. The Journal of Cell Biology 2004, 164(3):451-459.
305. Xiao J., Horst S., Hinkle G., Cao X., Kocak E., Fang J., et al. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients. Cancer Biotherapy & Radiopharmaceuticals 2005, 20(1):16-26.
306. Yamashita K., Tachibana Y., Ohkura T., Kobata A. Enzymatic basis for the structural changes of asparagine-linked sugar chains of membrane glycoproteins of baby hamster kidney cells induced by polyoma transformation. The Journal of Biological Chemistry 1985, 260(7):3963-3969.
307. Yang J.M., Byrd J.C., Siddiki B.B., Chung Y.S., Okuno M., Sowa M., et al. Alterations of O-glycan biosynthesis in human colon cancer tissues. Glycobiology 1994, 4(6):873-884.
308. Yang R.Y., Rabinovich G.A., Liu F.T. Galectins: Structure, function and therapeutic potential. Expert Reviews in Molecular Medicine 2008, 10:e17.
309. Yao Z., Sakahara H., Zhang M., Kobayashi H., Nakada H., Yamashina I., et al. Radioimmunoimaging of colon cancer xenografts with anti-Tn monoclonal antibody. Nuclear Medicine and Biology 1995, 22(2):199-203.
310. Yeh J.C., Hiraoka N., Petryniak B., Nakayama J., Ellies L.G., Rabuka D., et al. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase. Cell 2001, 105(7):957-969.
311. Yeh J.C., Ong E., Fukuda M. Molecular cloning and expression of a novel beta-1, 6-N-acetylglucosaminyltransferase that forms core 2, core 4, and I branches. The Journal of Biological Chemistry 1999, 274(5):3215-3221.
312. Yin B.W., Lloyd K.O. Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16. The Journal of Biological Chemistry 2001, 276(29):27371-27375.
313. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Research 1992, 52(12):3402-3408.
314. Yokota T., Milenic D.E., Whitlow M., Wood J.F., Hubert S.L., Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Research 1993, 53(16):3776-3783.
315. Young W.W., Holcomb D.R., Ten Hagen K.G., Tabak L.A. Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase isoforms in murine tissues determined by real-time PCR: A new view of a large family. Glycobiology 2003, 13(7):549-557.
316. Yu L.G. The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconjugate Journal 2007, 24(8):411-420.
317. Yu H., Chen X. Carbohydrate post-glycosylational modifications. Organic & Biomolecular Chemistry 2007, 5(6):865-872.
318. Yuan M. The expression of Tn and S-Tn antigens in cancer and pre-malignant lesion of colorectal tissues by enzyme immunohistochemical method. Zhonghua Bing Li Xue Za Zhi 1989, 18(3):211-213.
319. Yuan M., Itzkowitz S.H., Palekar A., Shamsuddin A.M., Phelps P.C., Trump B.F., et al. Distribution of blood group antigens A, B, H, Lewisa, and Lewisb in human normal, fetal, and malignant colonic tissue. Cancer Research 1985, 45(9):4499-4511.
320. Zhang M., Yao Z., Sakahara H., Saga T., Nakamoto Y., Sato N., et al. Effect of administration route and dose of streptavidin or biotin on the tumor uptake of radioactivity in intraperitoneal tumor with multistep targeting. Nuclear Medicine and Biology 1998, 25(2):101-105.
321. 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: Preliminary results. World Journal of Surgical Oncology 2010, 8:65.